Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Revenue grew $0.3 million sequentially from Q1, reaching a total of $3.1 million for the quarter reflects early commercial stabilization despite persistent academic and government funding pressures.
Management attributes the current revenue level to the 'nascent' stage of the deep proteomics market, where scientific validation precedes commercial inflection. The platform is being positioned as a critical data source for AI foundation models, providing 7x more data points and 11x more peptide-level measurements than high-plex targeted assays. Third-party validation from Roche and Nature Genetics studies confirms the Proteograph's superior depth and reproducibility compared to affinity-based competitors like Olink and SomaLogic.
Strategic focus has shifted toward large accounts and population-scale studies to drive meaningful, recurring revenue through high-volume consumable pull-through. The company is aggressively defending its intellectual property, citing recent favorable rulings from the U.S. PTAB and European Patent Office against competitors.
Full-year 2026 revenue guidance of $16 million to $18 million is reaffirmed, targeting revenue growth in the second half of 2026 to meet full-year revenue guidance of $16 million to $18 million. Guidance assumes that the challenging academic and government funding environment will persist through the remainder of 2026. Management expects the release of PRECISE-SG-100K data at the HUPO conference in September to serve as a catalyst for large-scale biobank commitments.
The commercial ramp is expected to build over several months as the new Chief Commercial Officer optimizes infrastructure for lean execution and capital discipline. Current cash reserves of $209.5 million are deemed sufficient to reach cash flow breakeven without requiring additional external capital. The share repurchase program has reduced net total common shares outstanding by approximately 15% to address perceived stock price dislocation.
Gross margins improved 1,300 basis points sequentially to 49%, though management expects continued quarterly variability based on product mix. Related party revenue from PrognomIQ has declined to nominal levels as they pivot toward lab-developed tests rather than discovery work. Legal and professional service expenses remained elevated due to ongoing patent infringement litigation and intellectual property defense.
Extract — continue reading at the source.
